Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Bethi Rathnakar has a total of 21 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Design, Synthesis and Evaluation of Hybrid 2-Heteroaryl Benzimidazole- Chalcone Derivatives as Anticancer Agents

    by Gajula Shyam Kumar, Bethi Rathnakar, Sridhar Gattu, Surender Singh Jadav, Nimma Rameshwar, Shireesha Boyapati, Mavurapu Satyanarayana

    A series of 2-heteroaryl benzimidazole-chalcone hybrids were synthesized and the anticancer activity was estimated by MTT assay in human breast, lung, colon, and ovarian cancer cell lines. The biological results indicate that the compounds showed good anticancer activity with IC50 value in the range of 0.056-19.5 μM. Compound 11b with hexa methoxy groups, bearing three methoxy groups on each terminal aryl ring exhibited a significant IC50 value (56 nM) against human breast carcinoma cells, which is 37 times higher potency in comparison with the reference Etoposide. Further compounds substituted variably with methoxy and nitro groups on the phenyl ring of chalcone showed more promising anticancer activity than the compounds with unsubstituted phenyl ring or variably alkyl-substituted phenyl ring of chalcone. The molecular docking results indicate that the synthesized compounds bind in the active site of Abl tyrosine kinase, the target of anticancer drug Imatinib. The present study provides the synergistic effect of hybrids, benzimidazole-chalcones as potential anticancer agents that will aid in the discovery of new anticancer agents.


  • Design, Synthesis of Biaryl Piperidine Derivatives and Their Evaluation as Potential Antileishmanial Agents against Leishmania donovani Strain Ag83

    by Bethi Rathnakar, Kislay Kumar Sinha, Surendra Rajit Prasad, Mohd. Imran Khan, Chelimela Narsaiah, Nimma Rameshwar, Mavurapu Satyanarayana

    We have developed a new series of simple biaryl piperidine derivatives (11–19) based on biaryl naphthylisoquinoline alkaloid Ealamine‐A. The target compounds were synthesized, analyzed by spectral data, and evaluated for antileishmanial activity against Leishmania donovani strain Ag83 by MTT assay. The compounds have shown the best to moderate antileishmanial activity. The 5′‐fluoro‐2′‐methoxyphenyl derivative 14 and 3′,5′‐difluorophenyl derivative 16 have inhibited the promastigotes by 86 % and 85 % after 24 h and 92 % and 91 % after 48 h incubation, respectively, at 400 μM concentration. The % inhibition was lower with the lowering of the concentration and increased with the incubation time. Compounds 12, 15, and 18 have solubility issues and proved to be less active than the rest of the compounds. Molecular docking studies were performed on selective active compounds and the results indicate that these compounds may act by binding to the Leishmanolysin and the docking scores are in good correlation with the antileishmanial activity. These results provide an initial insight into the design of new therapeutics for neglected tropical diseases.


  • Design, synthesis, and evaluation of novel combretastatin A‐4 based chalcone derivatives as anticancer agents

    by Bethi Rathnakar, Gajula S. Kumar, Saleem P. Mahammad, Sridhar Gattu, Sambaru Kalyani, Rameshwar Nimma, Mavurapu Satyanarayana

    A series of combretastatin A‐4 based chalcones (14a‐l) were designed, synthesized and these compounds examined for inhibitory effects on the proliferation of human lung (A549), breast (MCF‐7), melanoma (A375), and colon (HT‐29) carcinoma cells. Compounds 14b, 14c, 14e, 14h, and 14i (tri/dimethoxy, methyl, and mono/dinitro derivatives) have exhibited the most potent antiproliferative activity with IC50 < 2 μM and the hexa methoxy derivative 14b, the most promising one, which displayed the potent inhibitory activities in MCF‐7 (IC50: 10 nM), A375 (IC50: 12 nM), and A549 (IC50: 65 nM) cell lines, and is 18 times more potent than the CA‐4. Compound 14b represents a new scaffold and the results provide insights into further development of anticancer agents.


  • A review on HCV inhibitors: Significance of non-structural polyproteins

    by Narayana Murthy Ganta, Gangaraju Gedda, Bethi Rathnakar, Mavurapu Satyanarayana, Bhaskar Yamajala, Mohamed Jawed Ahsan, Surender Singh Jadav, Tuniki Balaraju